Listing Regulation | Nanologica

Nanologica offentliggör prospekt avseende företrädesemission

26 September, 2024

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA, ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDET, PUBLICERINGEN ELLER DISTRIBUTIONEN AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG, VARA FÖREMÅL FÖR LEGALA RESTRIKTIONER ELLER SKULLE KRÄVA REGISTRERING ELLER ANDRA ÅTGÄRDER. Nanologica AB (publ) (”Nanologica” eller ”Bolaget”) offentliggör prospekt med anledning av den företrädesemission av units motsvarande cirka 99,4 MSEK som beslutades av styrelsen den 29 augusti

Nanologica Publishes Prospectus in Connection with Rights Issue

26 September, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. Nanologica AB (publ) (”Nanologica” or the “Company”) publishes a prospectus in connection with the rights issue of units corresponding to

Bulletin from the Extraordinary General Meeting of Nanologica AB (publ)

23 September, 2024

Today Nanologica AB (publ) held an extraordinary general meeting whereby the following resolutions were adopted. For more detailed information on the content of the resolutions, please see the complete notice of the extraordinary general meeting that is available on the company’s website, www.nanologica.com. Determination of the number of board members, election of a new board member and determination of remunerationThe general meeting resolved to expand the board of directors from five to six members and to

Kommuniké från extra bolagsstämma i Nanologica AB (publ)

23 September, 2024

Nanologica AB (publ) höll idag extra bolagsstämma varvid följande beslut fattades. För mer detaljerad information om innehållet i besluten hänvisas till den fullständiga kallelsen till den extra bolagsstämman som finns tillgänglig på bolagets webbplats, www.nanologica.com. Beslut om antalet styrelseledamöter, val av ny styrelseledamot och beslut om arvodeBolagsstämman beslutade att utöka styrelsen från fem till sex ledamöter samt att välja Alexandra Blomberg Montgomery till ny styrelseledamot för tiden intill slutet av nästa årsstämma. Vidare beslutades att Alexandra

Förslag till förändring av styrelsen för Nanologica AB (publ)

2 September, 2024

Alexandra Blomberg Montgomery föreslås att vid den extra bolagsstämman 23 september 2024 väljas in som ny styrelseledamot i Nanologicas styrelse. Alexandra Blomberg Montgomery har lång erfarenhet av rådgivning till bolag verksamma inom många sektorer genom sina år som partner på KREAB där hon även innehaft flera ledande befattningar bl a inom internationell affärsutveckling. Vidare har Alexandra erfarenhet av medicinsk forskning utifrån ett styrelseperspektiv, exempelvis som styrelseledamot i Ragnar Söderbergs Stiftelse. Alexandra arbetar främst med investeringar i

Proposal for Change in the Board of Directors of Nanologica AB (publ)

2 September, 2024

Alexandra Blomberg Montgomery is proposed to be elected as a new member of the board of directors of Nanologica at the Extraordinary General Meeting on September 23, 2024. Alexandra Blomberg Montgomery has extensive experience in advising companies operating in several sectors through her years as a partner at KREAB, where she has also held several senior positions, including in international business development. Furthermore, Alexandra has experience of medical research from a board perspective, for example

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.